Crossmark

Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy

Crossref DOI link: https://doi.org/10.1007/s00330-021-08304-y

Published Online: 2021-10-19

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Noda, Yoshifumi

Pisuchpen, Nisanard

Mercaldo, Nathaniel D.

Sekigami, Yurie

Michelakos, Theodoros

Parakh, Anushri

Wo, Jennifer Y.

Qadan, Motaz

Ferrone, Cristina

Lillemoe, Keith D.

Ryan, David P.

Clark, Jeffrey W.

Fernandez-Del Castillo, Carlos

Hong, Theodore S.

Kambadakone, Avinash R.
License Information

Text and Data Mining valid from 2021-10-19

Version of Record valid from 2021-10-19
More Information

Article History

Received: 31 May 2021

Revised: 25 July 2021

Accepted: 25 August 2021

First Online: 19 October 2021

Declarations

:

: The scientific guarantor of this publication is Avinash Kambadakone.

: A.K.: Grant support for research activities from Philips, GE Healthcare, and PanCAN. Other authors report no relevant disclosures or conflicts of interest.

: No complex statistical methods were necessary for this paper.

: Informed consent was waived in this study because of retrospective design.

: Institutional Review Board approval was obtained.

: • Retrospective• Diagnostic or prognostic study• Performed at one institution

Document is current

Any future updates will be listed below